Evolution of the Average Target: Denali Therapeutics Inc.

Evolution of the Target Price: Denali Therapeutics Inc.

Changes in Analyst Recommendations: Denali Therapeutics Inc.

eabb4f3a2c545a1ef7bb273d.F9n4f6yPOg1sV2N1h2abOFZNfXuQmtDBOT-ZHxP77js.R-yaLdzVDUIFDzoQ0jGqfQUmHzDAqeale1DDclCL3F5buJs8zd1qZDQwKg~46cc84f1814a03681fa0c9bd13332e74
08-25 B. Riley Adjusts Denali Therapeutics Price Target to $35 From $30, Maintains Buy Rating MT
08-07 UBS Adjusts Price Target on Denali Therapeutics to $34 From $25, Maintains Buy Rating MT
08-07 Wedbush Adjusts PT on Denali Therapeutics to $27 From $26, Maintains Outperform Rating MT
07-16 Deutsche Bank Adjusts Price Target on Denali Therapeutics to $35 From $31, Maintains Buy Rating MT
07-13 Wedbush Raises Price Target on Denali Therapeutics to $26 From $20, Keeps Outperform Rating MT
05-26 Denali Therapeutics' Focus Shifts to Other Pipeline Assets After Phase 2b Study Failure, Morgan Stanley Says MT
05-22 Morgan Stanley Cuts Price Target on Denali Therapeutics to $35 From $40, Keeps Overweight Rating MT
05-22 Wedbush Cuts Price Target on Denali Therapeutics to $20 From $23, Keeps Outperform Rating MT
05-22 Deutsche Bank Adjusts Denali Therapeutics Price Target to $31 From $35, Maintains Buy Rating MT
05-14 Morgan Stanley Trims Price Target on Denali Therapeutics to $40 From $42, Keeps Overweight Rating MT
05-11 Denali Therapeutics Seeing Encouraging Signals From Avlayah Launch, Oppenheimer Says MT
05-08 Wedbush Adjusts Denali Therapeutics Price Target to $23 From $25, Maintains Outperform Rating MT
04-21 Wedbush Cuts Price Target on Denali Therapeutics to $25 From $30, Keeps Outperform Rating MT
03-26 Deutsche Bank Raises Price Target on Denali Therapeutics to $35 From $26, Keeps Buy Rating MT
03-26 Morgan Stanley Lifts Price Target on Denali Therapeutics to $42 From $40, Keeps Overweight Rating MT
01-07 UBS Adjusts Price Target on Denali Therapeutics to $25 From $24, Maintains Buy Rating MT
12-11 Wedbush Trims Price Target on Denali Therapeutics to $30 From $31, Keeps Outperform Rating MT
12-05 Wedbush Adjusts Denali Therapeutics Price Target to $31 From $30, Maintains Outperform Rating MT
11-17 Centessa Pharmaceuticals, CG Oncology Drive Q3 Biotech Momentum, Morgan Stanley Says MT
11-17 Morgan Stanley Raises Price Target on Denali Therapeutics to $32 From $30, Keeps Overweight Rating MT
25-10-13 Denali's FDA Approval for Hunter Syndrome's Drug Candidate Extended MT
25-10-13 Denali Therapeutics announces FDA review extension of BLA for Tividenofusp alfa RE
25-10-13 Denali Therapeutics Announces FDA Review Extension of BLA for Tividenofusp Alfa for the Treatment of MPS II (Hunter Syndrome) CI
25-05-08 B. Riley Adjusts Denali Therapeutics Price Target to $30 From $35, Maintains Buy Rating MT
25-05-08 Deutsche Bank Adjusts Denali Therapeutics Price Target to $28 From $29, Maintains Buy Rating MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+76.86%
+15.19%
+22.02%
+9.85%
+68.92%
+18.94%
+7.76%
+20.98%
-7.69%
+32.69%
Average +26.55%
Weighted average by Cap. +21.63%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
20.98USD
Average target price
36.06USD
Spread / Average Target
+71.89%
High Price Target
42.00USD
Spread / Highest target
+100.19%
Low Price Target
27.00USD
Spread / Lowest Target
+28.69%

Analyst Consensus Detail

Consensus revision (last 18 months)

Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
  1. Stock Market
  2. Stocks
  3. DNLI Stock
  4. Consensus Denali Therapeutics Inc.